- ReciBioPharm and Hongene Biotech have formed a strategic alliance to integrate sgRNA manufacturing into ReciBioPharm’s service portfolio.
- The partnership will streamline gene editing drug development by combining Hongene’s sgRNA synthesis technology with ReciBioPharm’s comprehensive CDMO services.
ReciBioPharm, a provider of advanced therapeutics contract manufacturing services, and Hongene Biotech Corporation, known for its expertise in nucleic acid manufacturing, have announced a strategic collaboration aimed at improving gene editing drug manufacturing. This partnership will see ReciBioPharm expand its service offerings to include sgRNA manufacturing, using Hongene’s new technology.
Hongene Biotech has developed a novel sgRNA synthesis process that reduces impurities typically found in conventional methods. This technology will now be integrated into ReciBioPharm’s services, which include plasmid, mRNA, LNP, and sterile drug product manufacturing. By incorporating sgRNA production, ReciBioPharm aims to provide a more streamlined and efficient development process.
The collaboration is expected to simplify the drug manufacturing process for gene editing, reducing the need for multiple CDMOs and accelerating development timelines. Vikas Gupta, President of ReciBioPharm, noted, “Our collaboration with Hongene Biotech marks an important step forward, enabling us to offer comprehensive solutions in the gene editing sector.”
Wei Jiang, CEO of Hongene Biotech, commented, “This partnership is set to redefine gene editing manufacturing, combining our sgRNA technology with ReciBioPharm’s mRNA and drug product manufacturing expertise.”
Stay ahead of trends and best practices
